Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia

Leukemia

Volumn 23, Issue 1, 2009, Pages 134-143

  Nebral, K ^a   Denk, D ^a   Attarbaschi, A ^a   Konig M ^a   Mann, G ^a   Haas, O A ^a   Strehl, S ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 1; JANUS KINASE 2; MEMBRANE PROTEIN; PROTEIN BRD1; PROTEIN DACH1; PROTEIN POM121; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFANT; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 58249118804     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.306     Document Type: Article

References (56)

1. Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol 2004; 22: 55-79.
2. Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science 2002; 297: 110-113.
3. Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 2001; 20: 65-82.
4. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999; 401: 556-562.
5. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006; 24 269-281.
6. Schebesta M, Heavey B, Busslinger M. Transcriptional control of B-cell development. Curr Opin Immunol 2002; 14: 216-223.
7. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 1996; 93: 6129-6134.
8. Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC et al The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996; 88: 4110-4117.
9. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
10. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001; 61: 4666-4670.
11. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 2003; 17: 1121-1123.
12. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood 2007; 109: 3417-3423.
13. Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol 2007; 139: 269-274.
14. Kawamata N, Ogawa S, Zimmermann M, Sanada M, Hemminki K, Yamatomo G et al. Rearrangement and deletion of the PAX5 gene in pediatric acute B-cell lineage lymphoblastic leukemia. ASH Annu Meet Abstr 2007; 110: 981.
15. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250.
16. Konig M, Reichel M, Marschalek R, Haas OA, Strehl S. A highly specific and sensitive fluorescence in situ hybridization assay for the detection of t(4;11)(q21;q23) and concurrent submicroscopic deletions in acute leukaemias. Br J Haematol 2002; 116: 758-764.
17. Ayres JA, Shum L, Akarsu AN, Dashner R, Takahashi K, Ikura T et al DACH: Genomic characterization, evaluation as a candidate for postaxial polydactyly type A2, and developmental expression pattern of the mouse homologue. Genomics 2001; 77: 18-26.
18. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-6737.
19. Murray PJ. The JAK-STAT signaling pathway: Input and output integration. J Immunol 2007; 178: 2623-2629.
20. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683.
21. Ihle JN, Gilliland DG. Jak2: Normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17: 8-14.
22. Poitras JL, Cin PD, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47 884-889.
23. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998; 17: 5321-5333.
24. Kovac CR, Emelyanov A, Singh M, Ashouian N, Birshtein BK. BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence. J Biol Chem 2000; 275: 16752-16757.
25. McCullagh P, Chaplin T, Meerabux J, Grenzelias D, Lillington D, Poulsom R et al. The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene. Oncogene 1999; 18 7442-7452.
26. Chaplin T, Bernard O, Beverloo HB, Saha V, Hagemeijer A, Berger R et al. The t(10;11) translocation in acute myeloid leukemia (M5) consistently fuses the leucine zipper motif of AF10 onto the HRX gene. Blood 1995; 86: 2073-2076.
27. Prasad R, Leshkowitz D, Gu Y, Alder H, Nakamura T, Saito H et al. Leucine-zipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia. Proc Natl Acad Sci USA 1994; 91: 8107-8111.
28. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8: 983-994.
29. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: Lessons from professional pocket pickers. Nat Struct Mol Biol 2007; 14: 1025-1040.
30. Arai S, Matsushita A, Du K, Yagi K, Okazaki Y, Kurokawa R. Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. FEBS Lett 2007; 581: 5649-5657.
31. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 1998; 273: 25875-25879.
32. Aikawa Y, Nguyen LA, Isono K, Takakura N, Tagata Y, Schmitz ML et al Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 2006; 25: 3955-3965.
33. Ecsedy JA, Michaelson JS, Leder P. Homeodomain-interacting protein kinase 1 modulates Daxx localization, phosphorylation, and transcriptional activity. Mol Cell Biol 2003; 23: 950-960.
34. Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A et al. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci USA 2003; 100: 5431-5436.
35. Li X, Zhang R, Luo D, Park SJ, Wang Q, Kim Y et al. Tumor necrosis factor alpha-induced desumoylation and cytoplasmic translocation of homeodomain-interacting protein kinase 1 are critical for apoptosis signal-regulating kinase 1-JNK/p38 activation. J Biol Chem 2005; 280: 15061-15070.
36. Rochat-Steiner V, Becker K, Micheau O, Schneider P, Burns K, Tschopp J. FIST/HIPK3: A Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J Exp Med 2000; 192: 1165-1174.
37. Chen R, Amoui M, Zhang Z, Mardon G. Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila. Cell 1997; 91: 893-903.
38. Davis RJ, Shen W, Heanue TA, Mardon G. Mouse Dach, a homologue of Drosophila dachshund, is expressed in the developing retina, brain and limbs. Dev Genes Evol 1999; 209: 526-536.
39. Kozmik Z, Pfeffer P, Kralova J, Paces J, Paces V, Kalousova A et al Molecular cloning and expression of the human and mouse homologues of the Drosophila dachshund gene. Dev Genes Evol 1999; 209: 537-545.
40. Wawersik S, Maas RL. Vertebrate eye development as modeled in Drosophila. Hum Mol Genet 2000; 9: 917-925.
41. Hanson IM. Mammalian homologues of the Drosophila eye specification genes. Semin Cell Dev Biol 2001; 12: 475-484.
42. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS et al Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66: 8404-8412.
43. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A et al. DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 2003; 278: 51673-51684.
44. Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X et al. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell 2007; 18: 755-767.
45. Hallberg E, Wozniak RW, Blobel G. An integral membrane protein of the pore membrane domain of the nuclear envelope contains a nucleoporin-like region. J Cell Biol 1993; 122: 513-521.
46. Gerace L, Ottaviano Y, Kondor-Koch C. Identification of a major polypeptide of the nuclear pore complex. J Cell Biol 1982; 95 826-837.
47. Antonin W, Franz C, Haselmann U, Antony C, Mattaj IW. The integral membrane nucleoporin pom121 functionally links nuclear pore complex assembly and nuclear envelope formation. Mol Cell 2005; 17: 83-92.
48. Stavru F, Nautrup-Pedersen G, Cordes VC, Gorlich D. Nuclear pore complex assembly and maintenance in POM121- and gp210-deficient cells. J Cell Biol 2006; 173: 477-483.
49. Lusk CP, Blobel G, King MC. Highway to the inner nuclear membrane: Rules for the road. Nat Rev Mol Cell Biol 2007; 8: 414-420.
50. Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N et al. NUP98 rearrangements in hematopoietic malignancies: A study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 2006; 20: 696-706.
51. Slape C, Aplan PD. The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 2004; 45: 1341-1350.
52. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
53. Soekarman D, von Lindern M, Daenen S, de Jong B, Fonatsch C, Heinze B et al. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 1992; 79: 2990-2997.
54. von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 1992; 5: 227-234.
55. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: The guardian of B cell identity and function. Nat Immunol 2007; 8: 463-470.
56. Fazio G, Palmi C, Rolink A, Biondi A, Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008; 68: 181-189.